NCT05868629View on ClinicalTrials.gov

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

May 4, 2028

Study Completion Date

May 4, 2028

Conditions
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Interventions
OTHER

Non-investigational

Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program

Trial Locations (6)

20016

RECRUITING

Johns Hopkins University, Washington D.C.

27704

RECRUITING

Duke Clinical Research Institute, Durham

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

45242

RECRUITING

Oncology Hematology Care Inc, Cincinnati

79902

RECRUITING

El Paso Texas Oncology, El Paso

90509-2910

RECRUITING

Lundquist Inst BioMed at Harbor, Torrance

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY